Compounds and uses thereof for the modulation of hemoglobin

Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Description

FIELD OF THE INVENTION

[0001] This invention provides compounds and pharmaceutical compositions suitable as allosteric modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

STATE OF THE ART

[0002] Sickle cell disease is a disorder of the red blood cells, found particularly among those of African and Mediterranean descent. The basis for sickle cell disease is found in sickle hemoglobin (HbS), which contains a point mutation relative to the prevalent peptide sequence of hemoglobin (Hb).

[0003] Hemoglobin (Hb) transports oxygen molecules from the lungs to various tissues and organs throughout the body. Hemoglobin binds and releases oxygen through conformational changes. Sickle hemoglobin (HbS) contains a point mutation where glutamic acid is replaced with valine, allowing HbS to become susceptible to polymerization to give the HbS containing red blood cells their characteristic sickle shape. The sickled cells are also more rigid than normal red blood cells, and their lack of flexibility can lead to blockage of blood vessels. U.S. Pat. No. 7,160,910 discloses compounds that are allosteric modulators of hemoglobin. However, a need exists for additional therapeutics that can treat disorders that are mediated by Hb or by abnormal Hb such as HbS.

SUMMARY OF THE INVENTION

[0004] This invention relates generally to compounds and pharmaceutical compositions suitable as allosteric modulators of hemoglobin. In some aspects, this invention relates to methods for treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

[0005] In certain aspects of the invention, a compound of formula (I) is provided:

##STR00001##

[0006] or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof, wherein

[0007] A is selected from the group consisting of:

##STR00002##

[0008] wherein R.sup.1 is C.sub.1-C.sub.6 alkyl optionally substituted with 3-6 fluoro atoms;

[0009] R.sup.2 is hydrogen or C.sub.1-C.sub.6 alkyl;

[0010] R.sup.3 is C.sub.1-C.sub.6 alkyl;

[0011] each R.sup.4 independently is hydrogen or C.sub.1-C.sub.6 alkyl;

[0012] ring B is

##STR00003##

[0013] or ring B together with A is:

##STR00004##

[0014] and stereoisomers thereof;

[0015] X is oxygen, S, SO, or SO.sub.2;

[0016] ring C is selected from the group consisting of:

##STR00005##

[0017] wherein R.sup.5 is selected from the group consisting of hydrogen; C.sub.1-C.sub.6 alkoxy, optionally substituted with a C.sub.1-C.sub.6 alkoxy group or with up to 3 fluoro atoms; C.sub.1-C.sub.6 alkyl; and halo;

[0018] R.sup.6 is hydrogen or halo;

[0019] R is hydrogen, a phosphate, a diphosphate, a phosphonate or a phosphoramidate containing moiety, or another promoiety;

[0020] provided that the compound of formula (I) comprises at least 1 OR group where R is not hydrogen.

[0021] In another aspect, this invention provides a compound of formula (II):

##STR00006##

[0022] wherein

[0023] R is hydrogen, a phosphate or a diphosphate containing moiety, or another promoiety; and

[0024] R.sup.1 is C.sub.1-C.sub.6 alkyl optionally substituted with 3-6 fluoro atoms; provided that the compound of formula (I) comprises at least 1 OR group where R is not hydrogen.

[0025] In further aspects, this invention provides a compound of formula (I) or formula (II), wherein R is --COR.sup.31, C(O)OR.sup.31, or CONR.sup.13R.sup.14,

[0026] each R.sup.31 is independently a C.sub.1-C.sub.6 alkyl; C.sub.3-C.sub.8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; and

[0027] R.sup.13 and R.sup.14 independently are C.sub.1-C.sub.6 alkyl; C.sub.3-C.sub.8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; or R.sup.13 and R.sup.14 together with the nitrogen atom they are bonded to for a 4-9 member heterocycle substituted with at least 1 amino, C.sub.1-C.sub.6 alkyl amino, or di C.sub.1-C.sub.6 alkylamino group.

[0028] In one embodiment, this invention provides a compound of formula (I) or formula (II), wherein R.sup.1 is isopropyl.

[0029] In certain aspects, this invention provides a compound of formula (II):

##STR00007##

wherein R is phosphate, C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35, or C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35; and wherein m, R.sup.1, R.sup.34 and R.sup.35 are defined as tabulated below:

TABLE-US-00001 R R.sup.1 m R.sup.34 R.sup.35 NR.sup.34R.sup.35 C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 2 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 3 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 4 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 2 ##STR00008## C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 3 ##STR00009## C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 4 ##STR00010## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 2 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 3 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 4 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 2 ##STR00011## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 3 ##STR00012## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 4 ##STR00013## P(O)(OH).sub.2 iso- propyl

an N oxide thereof, or a pharmaceutically acceptable salt of each thereof.

[0030] In further aspects of the invention, a composition is provided comprising any of the compounds described herein, and at least a pharmaceutically acceptable excipient.

[0031] In still further aspects of the invention, a method is provided for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.

[0032] In further aspects of the invention, a method is provided for treating oxygen deficiency associated with sickle cell anemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.

DETAILED DESCRIPTION OF THE INVENTION

[0033] It must be noted that as used herein and in the appended' claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a solvent" includes a plurality of such solvents.

[0034] As used herein, the term "comprising" or "comprises" is intended to mean that the compositions and methods include the recited elements, but not excluding others. "Consisting essentially of" when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition or process consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention. "Consisting of" shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.

[0035] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations. Each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. The term "about" when used before a numerical designation, e.g., temperature, time, amount, and concentration, including range, indicates approximations which may vary by (+) or (-) 10%, 5% or 1%.

[0036] As used herein, C.sub.m-C.sub.n, such as C.sub.1-C.sub.12, C.sub.1-C.sub.8, or C.sub.1-C.sub.6 when used before a group refers to that group containing m to n carbon atoms.

[0037] The term "alkoxy" refers to --O-alkyl.

[0038] The term "alkyl" refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 12 carbon atoms (i.e., C.sub.1-C.sub.12 alkyl) or 1 to 8 carbon atoms (i.e., C.sub.1-C.sub.8 alkyl), or 1 to 4 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH.sub.3--), ethyl (CH.sub.3CH.sub.2--), n-propyl (CH.sub.3CH.sub.2CH.sub.2--), isopropyl ((CH.sub.3).sub.2CH--), n-butyl (CH.sub.3CH.sub.2CH.sub.2CH.sub.2--), isobutyl ((CH.sub.3).sub.2CHCH.sub.2--), sec-butyl ((CH.sub.3)(CH.sub.3CH.sub.2)CH--), t-butyl ((CH.sub.3).sub.3C--), n-pentyl (CH.sub.3CH.sub.2CH.sub.2CH.sub.2CH.sub.2--), and neopentyl ((CH.sub.3).sub.3CCH.sub.2--).

[0039] The term "aryl" refers to a monovalent, aromatic mono- or bicyclic ring having 6-10 ring carbon atoms. Examples of aryl include phenyl and naphthyl. The condensed ring may or may not be aromatic provided that the point of attachment is at an aromatic carbon atom. For example, and without limitation, the following is an aryl group:

##STR00014##

[0040] The term "--CO.sub.2H ester" refers to an ester formed between the --CO.sub.2H group and an alcohol, preferably an aliphatic alcohol. A preferred example included --CO.sub.2R.sup.E, wherein R.sup.E is alkyl or aryl group optionally substituted with an amino group.

[0041] The term "chiral moiety" refers to a moiety that is chiral. Such a moiety can possess one or more asymmetric centers. Preferably, the chiral moiety is enantiomerically enriched, and more preferably a single enantiomer. Non limiting examples of chiral moieties include chiral carboxylic acids, chiral amines, chiral amino acids, such as the naturally occurring amino acids, chiral alcohols including chiral steroids, and the likes.

[0042] The term "cycloalkyl" refers to a monovalent, preferably saturated, hydrocarbyl mono-, bi-, or tricyclic ring having 3-12 ring carbon atoms. While cycloalkyl, refers preferably to saturated hydrocarbyl rings, as used herein, it also includes rings containing 1-2 carbon-carbon double bonds. Nonlimiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamentyl, and the like. The condensed rings may or may not be non-aromatic hydrocarbyl rings provided that the point of attachment is at a cycloalkyl carbon atom. For example, and without limitation, the following is a cycloalkyl group:

##STR00015##

[0043] The term "halo" refers to F, Cl, Br, and/or I.

[0044] The term "heteroaryl" refers to a monovalent, aromatic mono-, bi-, or tricyclic ring having 2-16 ring carbon atoms and 1-8 ring heteroatoms selected preferably from N, O, S, and P and oxidized forms of N, S, and P, provided that the ring contains at least 5 ring atoms. Nonlimiting examples of heteroaryl include furan, imidazole, oxadiazole, oxazole, pyridine, quinoline, and the like. The condensed rings may or may not be a heteroatom containing aromatic ring provided that the point of attachment is a heteroaryl atom. For example, and without limitation, the following is a heteroaryl group:

##STR00016##

[0045] The term "heterocyclyl" or heterocycle refers to a non-aromatic, mono-, bi-, or tricyclic ring containing 2-12 ring carbon atoms and 1-8 ring heteroatoms selected preferably from N, 0, S, and P and oxidized forms of N, S, and P, provided that the ring contains at least 3 ring atoms. While heterocyclyl preferably refers to saturated ring systems, it also includes ring systems containing 1-3 double bonds, provided that they ring is non-aromatic. Nonlimiting examples of heterocyclyl include, azalactones, oxazoline, piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuranyl, and tetrahydropyranyl. The condensed rings may or may not contain a non-aromatic heteroatom containing ring provided that the point of attachment is a heterocyclyl group. For example, and without limitation, the following is a heterocyclyl group:

##STR00017##

[0046] The term "hydrolyzing" refers to breaking an R.sup.H--O--CO--, R.sup.H--O--CS--, or an R.sup.H--O--SO.sub.2-- moiety to an R.sup.H--OH, preferably by adding water across the broken bond. A hydrolyzing is performed using various methods well known to the skilled artisan, non limiting examples of which include acidic and basic hydrolysis.

[0047] The term "oxo" refers to a C.dbd.O group, and to a substitution of 2 geminal hydrogen atoms with a C.dbd.O group.

[0048] The term "optionally substituted" refers to a substituted or unsubstituted group. The group may be substituted with one or more substituents, such as e.g., 1, 2, 3, 4 or 5 substituents. Preferably, the substituents are selected from the group consisting of oxo, halo, --CN, NO.sub.2, --N.sub.2+, --CO.sub.2R.sup.100, --OR.sup.100, --SR.sup.100, --SOR.sup.100, --SO.sub.2R.sup.100, --NR.sup.101R.sup.102, --CONR.sup.101R.sup.102, --.sub.2R.sup.101R.sup.102, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, --CR.sup.100.dbd.C(R.sup.100).sub.2, --CCR.sup.100, C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 heterocyclyl, C.sub.6-C.sub.12 aryl and C.sub.2-C.sub.12 heteroaryl, wherein each R.sup.100 independently is hydrogen or C.sub.1-C.sub.8 alkyl; C.sub.3-C.sub.12 cycloalkyl; C.sub.3-C.sub.10 heterocyclyl; C.sub.6-C.sub.12 aryl; or C.sub.2-C.sub.12 heteroaryl; wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with 1-3 halo, 1-3 C.sub.1-C.sub.6 alkyl, 1-3 C.sub.1-C.sub.6 haloalkyl or 1-3 C.sub.1-C.sub.6 alkoxy groups. Preferably, the substituents are selected from the group consisting of chloro, fluoro, --OCH.sub.3, methyl, ethyl, iso-propyl, cyclopropyl, vinyl, ethynyl, --CO.sub.2H, --CO.sub.2CH.sub.3, --OCF.sub.3, --CF.sub.3 and --OCHF.sub.2.

[0049] R.sup.101 and R.sup.102 independently is hydrogen; C.sub.1-C.sub.8 alkyl, optionally substituted with --CO.sub.2H or an ester thereof, C.sub.1-C.sub.6 alkoxy, oxo, --CR.sup.103.dbd.C(R.sup.103).sub.2, --CCR, C.sub.3-C.sub.10 cycloalkyl, C.sub.3-C.sub.10 heterocyclyl, C.sub.6-C.sub.12 aryl, or C.sub.2-C.sub.12 heteroaryl, wherein each R.sup.103 independently is hydrogen or C.sub.1-C.sub.8 alkyl; C.sub.3-C.sub.12 cycloalkyl; C.sub.3-C.sub.10 heterocyclyl; C.sub.6-C.sub.12 aryl; or C.sub.2-C.sub.12 heteroaryl; wherein each cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with 1-3 alkyl groups or 1-3 halo groups, or R.sup.101 and R.sup.102 together with the nitrogen atom they are attached to form a 5-7 membered heterocycle.

[0050] The term "pharmaceutically acceptable" refers to safe and non-toxic for in vivo, preferably, human administration.

[0051] The term "pharmaceutically acceptable salt" refers to a salt that is pharmaceutically acceptable.

[0052] The term "salt" refers to an ionic compound formed between an acid and a base. When the compound provided herein contains an acidic functionality, such salts include, without limitation, alkali metal, alkaline earth metal, and ammonium salts. As used herein, ammonium salts include, salts containing protonated nitrogen bases and alkylated nitrogen bases. Exemplary, and non-limiting cations useful in pharmaceutically acceptable salts include Na, K, Rb, Cs, NH.sub.4, Ca, Ba, imidazolium, and ammonium cations based on naturally occurring amino acids. When the compounds utilized herein contain basic functionally, such salts include, without limitation, salts of organic acids, such as carboxylic acids and sulfonic acids, and mineral acids, such as hydrogen halides, sulfuric acid, phosphoric acid, and the likes. Exemplary and non-limiting anions useful in pharmaceutically acceptable salts include oxalate, maleate, acetate, propionate, succinate, tartrate, chloride, sulfate, bisulfate, mono-, di-, and tribasic phosphate, mesylate, tosylate, and the likes.

[0053] The terms "treat", "treating" or "treatment", as used herein, include alleviating, abating or ameliorating a disease or condition or one or more symptoms thereof, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting or suppressing the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or suppressing the symptoms of the disease or condition, and are intended to include prophylaxis. The terms also include relieving the disease or conditions, e.g., causing the regression of clinical symptoms. The terms further include achieving a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the individual, notwithstanding that the individual is still be afflicted with the underlying disorder. For prophylactic benefit, the compositions are administered to an individual at risk of developing a particular disease, or to an individual reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.

[0054] The terms "preventing" or "prevention" refer to a reduction in risk of acquiring a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease). The terms further include causing the clinical symptoms not to develop, for example in a subject at risk of suffering from such a disease or disorder, thereby substantially averting onset of the disease or disorder.

[0055] The term "effective amount" refers to an amount that is effective for the treatment of a condition or disorder by an intranasal administration of a compound or composition described herein. In some embodiments, an effective amount of any of the compositions or dosage forms described herein is the amount used to treat a disorder mediated by hemoglobin or a disorder that would benefit from tissue and/or cellular oxygenation of any of the compositions or dosage forms described herein to a subject in need thereof.

[0056] The term "carrier" as used herein, refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells, e.g., red blood cells, or tissues.

[0057] As used herein, a "prodrug" is a compound that, after administration, is metabolized or otherwise converted to an active or more active form with respect to at least one property. To produce a prodrug, a pharmaceutically active compound can be modified chemically to render it less active or inactive, but the chemical modification is such that an active form of the compound is generated by metabolic or other biological processes. A prodrug may have, relative to the drug, altered metabolic stability or transport characteristics, fewer side effects or lower toxicity. For example, see the reference Nogrady, 1985, Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392. Prodrugs can also be prepared using compounds that are not drugs.

[0058] The invention provides prodrugs of substituted benzaldehyde compounds that increase oxygen affinity of hemoglobin S. The structures of the compounds, and derivatives thereof, as well as methods of their synthesis, pharmaceutical formulations thereof and methods of use are also provided.

Compounds

[0059] In certain aspects of the invention, a compound of formula (I) is provided:

##STR00018##

[0060] or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof, wherein

[0061] A is selected from the group consisting of:

##STR00019##

[0062] wherein R.sup.1 is C.sub.1-C.sub.6 alkyl optionally substituted with 3-6 fluoro atoms;

[0063] R.sup.2 is hydrogen or C.sub.1-C.sub.6 alkyl;

[0064] R.sup.3 is C.sub.1-C.sub.6 alkyl;

[0065] each R.sup.4 independently is hydrogen or C.sub.1-C.sub.6 alkyl;

[0066] ring B is

##STR00020##

[0067] or ring B together with A is:

##STR00021##

[0068] X is oxygen, S, SO, or SO.sub.2;

[0069] ring C is selected from the group consisting of:

##STR00022##

[0070] wherein R.sup.5 is selected from the group consisting of hydrogen; C.sub.1-C.sub.6 alkoxy, optionally substituted with a C.sub.1-C.sub.6 alkoxy group or with up to 3 fluoro atoms; C.sub.1-C.sub.6 alkyl; and halo;

[0071] R.sup.6 is hydrogen or halo;

[0072] R is hydrogen, a phosphate, a diphosphate, a phosphonate or a phosphoramidate containing moiety, or another promoiety;

[0073] provided that the compound of formula (I) comprises at least 1 OR group where R is not hydrogen; and

[0074] the promoieties are structurally and functionally defined herein.

[0075] In certain embodiments, a compound of formula (II) is provided:

##STR00023##

[0076] wherein

[0077] R is hydrogen, a phosphate, a diphosphate, a phosphonate or a phosphoramidate containing moiety, or another promoiety;

[0078] R.sup.1 is C.sub.1-C.sub.6 alkyl optionally substituted with 3-6 fluoro atoms;

[0079] provided that the compound of formula (I) comprises at least 1 OR group where R is not hydrogen and

[0080] the promoieties are structurally and functionally defined herein.

[0081] In one aspect, R is hydrogen, a phosphate, a diphosphate, a phosphonate or a phosphoramidate containing moiety, or another promoiety or prodrug moiety. Preferably the prodrug moiety imparts at least a 2 fold, more preferably a 4 fold, enhanced solubility and/or bioavailability to the active moiety (where R is hydrogen), and more preferably is hydrolyzed in vivo. The promoieties are structurally and functionally defined herein.

[0082] In one embodiments, R is --COR.sup.90, CO.sub.2R.sup.91, or CONR.sup.92R.sup.93 wherein

[0083] R.sup.90 and R.sup.91 independently are C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, each containing at least 1 basic nitrogen moiety; and

[0084] R.sup.92 and R.sup.93 independently are C.sub.1-C.sub.6 alkyl; C.sub.3-C.sub.8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, each containing at least 1 basic nitrogen moiety; or R.sup.92 and R.sup.93 together with the nitrogen atom they are bonded to for a 4-9 member heterocycle substituted with at least 1 amino, C.sub.1-C.sub.6 alkyl amino, or di C.sub.1-C.sub.6 alkylamino group.

[0085] In certain embodiments, R is --C(O)R.sup.31, C(O)OR.sup.31, or CONR.sup.13R.sup.14, each R.sup.31 is independently a C.sub.1-C.sub.6 alkyl; C.sub.3-C.sub.8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; and

[0086] R.sup.13 and R.sup.14 independently are C.sub.1-C.sub.6 alkyl; C.sub.3-C.sub.8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; or R.sup.13 and R.sup.14 together with the nitrogen atom they are bonded to for a 4-9 member heterocycle substituted with at least 1 amino, C.sub.1-C.sub.6 alkyl amino, or di C.sub.1-C.sub.6 alkylamino group.

[0087] Preferably, R.sup.1 is isopropyl.

[0088] In one aspect, R is C(O)OR.sup.31, C(S)OR.sup.31, C(O)SR.sup.31 or COR.sup.31, wherein R.sup.31 is as defined herein.

[0089] In one embodiment, R.sup.31 is a group of the formula (CR.sup.32R.sup.33).sub.eNR.sup.34R.sup.35, wherein each R.sup.32 and R.sup.33 is independently H, a C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.3-C.sub.9 heteroaryl or R.sup.32 and R.sup.33 together with the carbon atom they are bond to form a C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.3-C.sub.9 heterocyclyl or C.sub.3-C.sub.9 heteroaryl ring system, or 2 adjacent R.sup.32 moieties or 2 adjacent R.sup.33 moieties together with the carbon atom they are bond to form a C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.3-C.sub.9 heterocyclyl or C.sub.3-C.sub.9 heteroaryl ring system;

[0090] each R.sup.34 and R.sup.35 is a C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.3-C.sub.8 cycloalkyl, or R.sup.34 and R.sup.35 together with the nitrogen atom they are bond to form a C.sub.3-C.sub.8 cycloalkyl or C.sub.3-C.sub.9 heterocyclyl ring system;

[0091] each heterocyclic and heteroaryl ring system is optionally substituted with C.sub.1-C.sub.3 alkyl, --OH, amino and carboxyl groups; and

[0092] e is an integer of from 1 to 4:

[0093] In some less preferred embodiments R.sup.34 and R.sup.35 can be hydrogen.

[0094] In one embodiment, the subscript e is preferably 2 and each R.sup.32 and R.sup.33 is preferably independently selected from the group, H, CH.sub.3, and a member in which R.sup.32 and R.sup.33 are joined together to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 1,1-dioxo-hexahydro-1.DELTA..sup.6-thiopyran-4-yl or tetrahydropyran-4-yl group.

[0095] With regard to the prodrug group, preferred embodiments are compounds wherein NR.sup.34R.sup.35 is morpholino.

[0096] In one embodiment, R is:

##STR00024##

[0097] wherein

[0098] each R.sup.32 and R.sup.33 is independently H, C.sub.1-C.sub.8 alkyl, or optionally, if both present on the same substituent, may be joined together to form a C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.3-C.sub.9 heterocyclyl or C.sub.3-C.sub.9 heteroaryl ring system.

[0099] Within this embodiment, each R.sup.32 and R.sup.33 is independently, H, CH.sub.3, or are joined together to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1,1-dioxo-hexahydro-1.lamda..sup.6-thiopyran-4-yl or tetrahydropyran-4-yl group.

[0100] In a preferred embodiment, linkage of the prodrug moiety to the rest of the active molecule is stable enough so that the serum half life of the prodrug is from about 8 to about 24 hours.

[0101] In an embodiment of the invention, the prodrug moiety comprises a tertiary amine having a pKa near the physiological pH of 7.5. Any amines having a pKa within 1 unit of 7.5 are suitable alternatives amines for this purpose. The amine may be provided by the amine of a morpholino group. This pKa range of 6.5 to 8.5 allows for significant concentrations of the basic neutral amine to be present in the mildly alkaline small intestine. The basic, neutral form of the amine prodrug is lipophilic and is absorbed through the wall of the small intestine into the blood. Following absorption into the bloodstream, the prodrug moiety is cleaved by esterases which are naturally present in the serum to release an active compound.

[0102] Examples of R include, without limitation:

##STR00025## ##STR00026##

[0103] In another embodiment, R is as tabulated below:

TABLE-US-00002 R R.sup.1 m R.sup.34 R.sup.35 NR.sup.34R.sup.35 C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 2 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 3 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 4 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 2 ##STR00027## C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 3 ##STR00028## C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 4 ##STR00029## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 2 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 3 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 4 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 2 ##STR00030## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 3 ##STR00031## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 4 ##STR00032## P(O)(OH).sub.2 iso- propyl

an N oxide thereof, or a pharmaceutically acceptable salt of each thereof.

[0104] In another aspect, R is,

##STR00033##

[0105] wherein

[0106] R.sup.36 is lower alkyl (e.g. C.sub.1-C.sub.6 alkyl).

[0107] In yet another aspect, R is:

##STR00034##

[0108] wherein X.sup.1, Y.sup.1 and X.sup.2 are as defined herein.

[0109] In one embodiment, X.sup.1 is selected from the group consisting of O, S and NR.sup.37 wherein R.sup.37 is hydrogen or C.sub.1-C.sub.6 alkyl;

[0110] Y.sup.1 is --C(R.sup.38).sub.2 or a sugar moiety, wherein each R.sup.38 is independently hydrogen or C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl;

[0111] X.sup.2 is selected from the group consisting of halogen, C.sub.1-C.sub.6 alkoxy, diacylglycerol, amino, C.sub.1-C.sub.6 alkylamino, C.sub.1-C.sub.6 dialkylamino, C.sub.1-C.sub.6 alkylthio, a PEG moiety, a bile acid moiety, a sugar moiety, an amino acid moiety, a di- or tri-peptide, a PEG carboxylic acid, and -U-V wherein

[0112] U is O or S; and

[0113] V is selected from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, C.sub.3-C.sub.9 heteroaryl, C(W.sup.2)X.sup.3, PO(X.sup.3).sub.2, and SO.sub.2X.sup.3;

[0114] wherein W.sup.2 is O or NR.sup.39

[0115] wherein R.sup.39 is hydrogen or C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl; and

[0116] each X.sup.3 is independently amino, hydroxyl, mercapto, C.sub.1-C.sub.6 alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylamino, C.sub.1-C.sub.6 dialkylamino, C.sub.1-C.sub.6 alkylthio, a bile acid based alkoxy group, a sugar moiety, a PEG moiety, and --O--CH.sub.2--CH(OR.sup.40)CH.sub.2X.sup.4R.sup.40,

[0117] wherein:

[0118] X.sup.4 is selected from the group consisting of O, S, S.dbd.O, and SO.sub.2; and

[0119] each R.sup.40 is independently C.sub.10-C.sub.22 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl, C.sub.1-C.sub.8 alkylene, or C.sub.1-C.sub.8 heteroalkylene.

[0120] Each heterocyclic and heteroaryl ring system is optionally substituted with C.sub.1-C.sub.3 alkyl, --OH, amino and carboxyl groups.

[0121] In one embodiment, the present invention utilizes the following Y' groups: CH.sub.2, CHMe, CH(isopropyl), CH(tertiarybutyl), C(Me).sub.2, C(Et).sub.2, C(isopropyl).sub.2, and C(propyl).sub.2.

[0122] In another embodiment, the present invention utilizes the following X.sup.2 groups:

##STR00035##

[0123] --OMe, --OEt, --O-isopropyl, O-isobutyl, O-tertiarybutyl, --O--COMe, --O--C(.dbd.O)(isopropyl), --O--C(.dbd.O)(isobutyl), --O--C(.dbd.O)(tertiarybutyl), --O--C(.dbd.O)--NMe.sub.2, --O--C(.dbd.O)--NHMe, --O--C(.dbd.O)--NH.sub.2, --O--C(.dbd.O)--N(H)--CH(R.sup.41)--CO.sub.2Et wherein R.sup.41 is a side chain C.sub.1-C.sub.6 alkyl, or C.sub.3-C.sub.9 heterocyclyl group selected from the side chain groups present in essential amino acids; --O--P(.dbd.O)(OMe).sub.2, --O--P(.dbd.O)(O-isopropyl).sub.2, and --O--P(.dbd.O)(O-isobutyl).sub.2. Each heterocyclic is optionally substituted with one or more, preferably, 1-3, C.sub.1-C.sub.3 alkyl, --OH, amino and/or carboxyl groups.

[0124] In another embodiment, In one embodiment, R is:

##STR00036##

[0125] wherein

[0126] X.sup.3 is independently C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl; and

[0127] R.sup.42 is independently hydrogen or C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl.

[0128] Each heterocyclic is optionally substituted with one or more, preferably, 1-3, C.sub.1-C.sub.3 alkyl, --OH, amino and/or carboxyl groups.

[0129] In one embodiment, R is:

##STR00037##

[0130] wherein

[0131] each X.sup.3 is independently amino, hydroxyl, mercapto, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylamino, C.sub.1-C.sub.6 dialkylamino, C.sub.1-C.sub.6 alkylthio, a bile acid based alkoxy group, a sugar moiety, a PEG moiety, and --O--CH.sub.2--CH(OR.sup.40)CH.sub.2X.sup.4R.sup.40,

[0132] wherein:

[0133] X.sup.4 is selected from the group consisting of O, S, S.dbd.O, and SO.sub.2; and

[0134] each R.sup.4.degree. is independently C.sub.10-C.sub.22 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, C.sub.3-C.sub.9 heteroaryl, C.sub.1-C.sub.8 alkylene, or C.sub.1-C.sub.8 heteroalkylene; and

[0135] R.sup.42 is independently hydrogen or C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl.

[0136] In some embodiments, R.sup.42 is independently hydrogen or C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl; and each X.sup.3 independently is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylamino, C.sub.1-C.sub.6 dialkylamino, or C.sub.1-C.sub.6 alkylthio.

[0137] In some embodiments, R is represented by the following structures:

##STR00038## ##STR00039##

[0138] wherein, in the above examples, R.sup.43 is C.sub.10-C.sub.22 alkyl or alkylene, R.sup.44 is H or C.sub.1-C.sub.6 alkyl and R.sup.45 represents side chain alkyl groups present in naturally occurring alpha amino acids;

##STR00040##

[0139] wherein R.sup.46 is (CH.sub.2).sub.n, f=2-4, and CO--R.sup.47--NH.sub.2 represents an aminoacyl group; or

##STR00041##

[0140] wherein R.sup.46 is (CH.sub.2).sub.n, =2-4, R.sup.47 is (CH.sub.2).sub.n, n=1-3 and R.sup.49 is O or NMe.

[0141] In one embodiment, R is:

##STR00042##

[0142] In one aspect, R is --C(R.sup.200R.sup.201)O(R.sup.202R.sup.203)P(O)OR.sup.204NR.sup.205R.sup- .206, wherein each R.sup.200, R.sup.201, R.sup.202, R.sup.203, R.sup.204 R.sup.205 and R.sup.206 is independently H, a C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.3-C.sub.9 heteroaryl, wherein each alkyl, heterocyclyl, cycloalkyl, aryl, and heteroaryl is optionally substituted.

[0143] In some embodiments, R is --CH(R.sup.201)OCH.sub.2P(O)OR.sup.204NHR.sup.206, wherein R.sup.201 is C.sub.1-C.sub.8 alkyl, R.sup.204 is phenyl, optionally substituted. In one embodiment, R.sup.206 is --CHR.sup.207C(O)OR.sup.208 wherein R.sup.207 is selected from the group consisting of the naturally occurring amino acid side chains and --CO.sub.2H esters thereof and R.sup.208 is C.sub.1-C.sub.8 alkyl. In one embodiment, R.sup.206 is C.sub.1-C.sub.6 alkyl, optionally substituted with 1-3, CO.sub.2H, SH, NH.sub.2, C.sub.6-C.sub.10 aryl, and C.sub.2-C.sub.10 heteroaryl.

[0144] In one embodiment, R is:

##STR00043##

[0145] In one embodiment, R is:

##STR00044##

[0146] wherein Y.sup.1 is --C(R.sup.38).sub.2, wherein each R.sup.38 is independently hydrogen or C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl.

[0147] Various polyethylene glycol (PEG) moieties and synthetic methods related to them that can be used or adapted to make compounds of the invention are described in U.S. Pat. Nos. 6,608,076; 6,395,266; 6,194,580; 6,153,655; 6,127,355; 6,111,107; 5,965,566; 5,880,131; 5,840,900; 6,011,042 and 5,681,567.

[0148] In one embodiment, R is

##STR00045##

[0149] wherein

[0150] R.sup.50 is --OH or hydrogen;

[0151] R.sup.51 is --OH, or hydrogen;

[0152] W is --CH(CH.sub.3)W.sup.1;

[0153] wherein W.sup.1 is a substituted C.sub.1-C.sub.8 alkyl group containing a moiety which is optionally negatively charged at physiological pH,

[0154] said moiety is selected from the group consisting of CO.sub.2H, SO.sub.3H, SO.sub.2H, --P(O)(OR.sup.52)(OH), --OP(O)(OR.sup.52)(OH), and OSO.sub.3H,

[0155] wherein R.sup.52 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl.

[0156] Each heterocyclic and heteroaryl ring system is optionally substituted with one or more, preferably 1-3, C.sub.1-C.sub.3 alkyl, --OH, amino and/or carboxyl groups.

[0157] In one embodiment, R is:

##STR00046##

[0158] wherein R.sup.53 is H or C.sub.1-C.sub.6 alkyl.

[0159] In another aspect, R is SO.sub.3H.

[0160] In another aspect, R comprises a cleavable linker, wherein the term "cleavable linker" refers to a linker which has a short half life in vivo. The breakdown of the linker Z in a compound releases or generates the active compound. In one embodiment, the cleavable linker has a half life of less than ten hours. In one embodiment, the cleavable linker has a half life of less than an hour. In one embodiment, the half life of the cleavable linker is between one and fifteen minutes. In one embodiment, the cleavable linker has at least one connection with the structure: C*--C(.dbd.X*)X*--C* wherein C* is a substituted or unsubstituted methylene group, and X* is S or O. In one embodiment, the cleavable linker has at least one C*--C(.dbd.O)O--C* connection. In one embodiment, the cleavable linker has at least one C*--C(.dbd.O)S--C* connection. In one embodiment, the cleavable linker has at least one --C(.dbd.O)N*--C*--SO.sub.2--N*-connection, wherein N* is --NH-- or C.sub.1-C.sub.6 alkylamino. In one embodiment, the cleavable linker is hydrolyzed by an esterase enzyme.

[0161] In one embodiment, the linker is a self-immolating linker, such as that disclosed in U.S. patent publication 2002/0147138, to Firestone; PCT Appl. No. US05/08161 and PCT Pub. No. 2004/087075. In another embodiment, the linker is a substrate for enzymes. See generally Rooseboom et al., 2004, Pharmacol. Rev. 56:53-102.

Pharmaceutical Compositions

[0162] In further aspects of the invention, a composition is provided comprising any of the compounds described herein, and at least a pharmaceutically acceptable excipient.

[0163] In another aspect, this invention provides a composition comprising any of the compounds described herein, and a pharmaceutically acceptable excipient.

[0164] Such compositions can be formulated for different routes of administration. Although compositions suitable for oral delivery will probably be used most frequently, other routes that may be used include transdermal, intravenous, intraarterial, pulmonary, rectal, nasal, vaginal, lingual, intramuscular, intraperitoneal, intracutaneous, intracranial, and subcutaneous routes. Suitable dosage forms for administering any of the compounds described herein include tablets, capsules, pills, powders, aerosols, suppositories, parenterals, and oral liquids, including suspensions, solutions and emulsions. Sustained release dosage forms may also be used, for example, in a transdermal patch form. All dosage forms may be prepared using methods that are standard in the art (see e.g., Remington's Pharmaceutical Sciences, 16.sup.th ed., A. Oslo editor, Easton Pa. 1980).

[0165] Pharmaceutically acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of this invention. Such excipients may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art. Pharmaceutical compositions in accordance with the invention are prepared by conventional means using methods known in the art.

[0166] The compositions disclosed herein may be used in conjunction with any of the vehicles and excipients commonly employed in pharmaceutical preparations, e.g., talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous solvents, oils, paraffin derivatives, glycols, etc. Coloring and flavoring agents may also be added to preparations, particularly to those for oral administration. Solutions can be prepared using water or physiologically compatible organic solvents such as ethanol, 1,2-propylene glycol, polyglycols, dimethylsulfoxide, fatty alcohols, triglycerides, partial esters of glycerin and the like.

[0167] Solid pharmaceutical excipients include starch, cellulose, hydroxypropyl cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. In certain embodiments, the compositions provided herein comprises one or more of .alpha.-tocopherol, gum arabic, and/or hydroxypropyl cellulose.

[0168] In one embodiment, this invention provides sustained release formulations such as drug depots or patches comprising an effective amount of a compound provided herein. In another embodiment, the patch further comprises gum Arabic or hydroxypropyl cellulose separately or in combination, in the presence of alpha-tocopherol. Preferably, the hydroxypropyl cellulose has an average MW of from 10,000 to 100,000. In a more preferred embodiment, the hydroxypropyl cellulose has an average MW of from 5,000 to 50,000.

[0169] Compounds and pharmaceutical compositions of this invention maybe used alone or in combination with other compounds. When administered with another agent, the co-administration can be in any manner in which the pharmacological effects of both are manifest in the patient at the same time. Thus, co-administration does not require that a single pharmaceutical composition, the same dosage form, or even the same route of administration be used for administration of both the compound of this invention and the other agent or that the two agents be administered at precisely the same time. However, co-administration will be accomplished most conveniently by the same dosage form and the same route of administration, at substantially the same time. Obviously, such administration most advantageously proceeds by delivering both active ingredients simultaneously in a novel pharmaceutical composition in accordance with the present invention.

Methods of Treatment

[0170] In aspects of the invention, a method is provided for increasing tissue and/or cellular oxygenation, the method comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.

[0171] In aspects of the invention, a method is provided for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.

[0172] In aspects of the invention, a method is provided for treating a condition associated with oxygen deficiency, the method comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.

[0173] In further aspects of the invention, a method is provided for treating oxygen deficiency associated with sickle cell anemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.

[0174] In further aspects of the invention, a method is provided for treating sickle cell disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the compounds or compositions described herein. In still further aspects of the invention, a method is provided for treating cancer, a pulmonary disorder, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer's disease, acute respiratory disease syndrome, and a wound, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the compounds or compositions described herein.

Synthetic Methods

[0175] Certain methods for making the compounds described herein are also provided. The reactions are preferably carried out in a suitable inert solvent that will be apparent to the skilled artisan upon reading this disclosure, for a sufficient period of time to ensure substantial completion of the reaction as observed by thin layer chromatography, .sup.1H-NMR, etc. If needed to speed up the reaction, the reaction mixture can be heated, as is well known to the skilled artisan. The final and the intermediate compounds are purified, if necessary, by various art known methods such as crystallization, precipitation, column chromatography, and the likes, as will be apparent to the skilled artisan upon reading this disclosure.

[0176] An illustrative and non-limiting method for synthesizing a compound of formula (I), is schematically shown below.

[0177] In the Schemes below as well as throughout the application, the following abbreviations have the following meanings. If not defined, the terms have their generally accepted meanings. [0178] .degree. C.=degrees Celsius [0179] RT=Room temperature [0180] min=minute(s) [0181] h=hour(s) [0182] .mu.L=Microliter [0183] mL=Milliliter [0184] mmol=Millimole [0185] eq=Equivalent [0186] mg=Milligram [0187] ppm=Parts per million [0188] LC-MS=Liquid chromatography-mass spectrometry [0189] HPLC=High performance liquid chromatography [0190] NMR=Nuclear magnetic resonance [0191] Ph.sub.3PBr.sub.2=Triphenylphosphine dibromide [0192] DMF=N, N-Dimethylformamide [0193] DCM=Dichloromethane [0194] THF=Tetrahydrofuran [0195] DIAD=Diisopropyl azodicarboxylate [0196] DEAD=Diethyl azodicarboxylate

[0197] In the following Schemes, "A" refers to substituent "A" as described herein.

##STR00047##

refers aryl or heteroaryl members of substituent "A" as described herein.

##STR00048##

refer to rings B and C as described herein.

##STR00049##

[0198] General Method a (Scheme 1) for Preparing Aryloxy/Heteroarylether Analogs (4a/4b) from Substituted Methylene Alcohol (1) and Hydroxyl (Hetero)Aryl Aldehyde Derivatives (3a/3b).

[0199] A hydroxyl (hetero)arylaldehyde derivatives (3a/3b) (0.1-2 mmol) mixture with substituted methylene alcohol (1) (0.8 to 1.2 eq) and PPh.sub.3 (1-1.5 eq) in anhydrous THF (1-10 mL) was stirred under nitrogen until complete dissolution. The solution was cooled to 0.degree. C. on ice bath and DIAD or DEAD (1.1 eq) in THF or toluene was added dropwise over a 1-20 min period. The ice cooling bath was allowed to expire over 90 min and the mixture was stirred at RT for 2-48 hours. The mixture was stirred for 10 min, then filtered through a pad of silica. The silica was washed with ethyl acetate 2-20 mL. The combined filtrates were evaporated and the residue was dried on highvac. The residue was purified by preparative HPLC or flash silica gel chromatography.

[0200] General Method a (Scheme 1) for Preparing Aryloxy/Heteroarylether Analogs (4a/4b) from Substituted Methylene Halide (2) and Hydroxyl (Hetero)Aryl Aldehyde Derivatives (3a/3b).

[0201] A mixture of hydroxyl (hetero)arylaldehyde derivatives (3a/3b) (0.1-2 mmol, 1-4 eq.), substituted methylene chloride or bromide (2) (1 eq), and K.sub.2CO.sub.3 (2-5 eq.) (catalytic amount of NaI or Bu.sub.4NI may also be added) in DMF or acetonitrile (1 to 10 mL) was stirred at RT or heating up to 120.degree. C. for 0.5-8 h under nitrogen atmosphere. In workup A, water was added to the reaction mixture, the precipitated product was collected, washed with water, and then subjected to preparative HPLC or flash silica gel chromatography purification. In workup B (for products that did not precipitate), diluted HCl or aqueous NH.sub.4Cl was added at 0.degree. C. to adjusted the pH to .about.7, the reaction mixture was partitioned between ethyl acetate or dichloromethane and aqueous sodium chloride and the organic layer separated, dried, and solvent removed under vacuum to afford crude product which was purified by automated silica gel column chromatography using appropriate solvents mixture (e.g., ethyl acetate/hexanes).

[0202] General Method C for Preparing Substituted Methylene Chloride (2a).

[0203] To a solution of substituted methylene alcohol (1) (0.1 to 2 mmol) in DCM (1-10 mL) was added SOCl.sub.2 dropwise (2 eq to 5 eq) at 0.degree. C. or RT. The reaction mixture was stirred at RT for 10 min to 6 h, or until reaction is judged complete (LC/MS). The reaction mixture is concentrated to dryness over a rotavap. The crude chloride residue was suspended in toluene, sonicated and concentrated to dryness. The process was repeated three times and dried under vacuum to give the substituted methylene chloride (2), usually as an off-white solid, which was used for next step without further purification. Alternatively, a solution of aqueous IN Na.sub.2CO.sub.3 is then added to produce a solution of pH.about.8. the mixture was extracted with DCM (3.times.10-50 mL), dried over sodium sulfate, and concentrated to the crude substituted methylene chloride (2a), which is then purified by column chromatography on silica gel (0-100% ethyl acetate-hexanes).

[0204] General Method D for Preparing Substituted Methylene Bromide (2b).

[0205] To a solution of substituted methylene alcohol (1) (0.1 to 2 mmol) in DCM (1-10 mL) was added Ph.sub.3PBr.sub.2 dropwise (2 eq to 5 eq) at 0.degree. C. or RT. The reaction mixture was stirred at RT for 10 min to 2 h, or until reaction is judged complete (LC/MS). The reaction mixture is concentrated to dryness over a rotavap. The residue purified by column chromatography on silica gel (0-100% ethyl acetate-hexanes) to afford the pure bromide 2b.

[0206] Syntheses of the ester prodrugs start with the free carboxylic acid bearing the tertiary amine. The free acid is activated for ester formation in an aprotic solvent and then reacted with a free alcohol group in the presence of an inert base, such as triethyl amine, to provide the ester prodrug. Activating conditions for the carboxylic acid include forming the acid chloride using oxalyl chloride or thionyl chloride in an aprotic solvent, optionally with a catalytic amount of dimethyl formamide, followed by evaporation. Examples of aprotic solvents, include, but are not limited to methylene chloride, tetrahydrofuran, and the like. Alternatively, activations can be performed in situ by using reagents such as BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorolphosphate, and the like (see Nagy et al., 1993, Proc. Natl. Acad. Sci. USA 90:6373-6376) followed by reaction with the free alcohol. Isolation of the ester products can be affected by extraction with an organic solvent, such as ethyl acetate or methylene chloride, against a mildly acidic aqueous solution; followed by base treatment of the acidic aqueous phase so as to render it basic; followed by extraction with an organic solvent, for example ethyl acetate or methylene chloride; evaporation of the organic solvent layer; and recrystallization from a solvent, such as ethanol. Optionally, the solvent can be acidified with an acid, such as HCl or acetic acid to provide a pharmaceutically acceptable salt thereof. Alternatively the crude reaction can be passed over an ion exchange column bearing sulfonic acid groups in the protonated form, washed with deionized water, and eluted with aqueous ammonia; followed by evaporation.

[0207] Suitable free acids bearing the tertiary amine are commercially available, such as 2-(N-morpholino)-propionic acid, N,N-dimethyl-beta-alanine, and the like. Non-commercial acids can be synthesized in straightforward manner via standard literature procedures.

[0208] Carbonate and carbamate prodrugs can be prepared in an analogous way. For example, amino alcohols and diamines can be activated using activating agents such as phosgene or carbonyl diimidazole, to provide an activated carbonates, which in turn can react with the alcohol and/or the phenolic hydroxy group on the compounds utilized herein to provide carbonate and carbamate prodrugs.

[0209] Various protecting groups and synthetic methods related to them that can be used or adapted to make compounds of the invention can be adapted from the references Testa et al., Hydrolysis in Drug and Prodrug Metabolism, June 2003, Wiley-VCH, Zurich, 419-534 and Beaumont et al., Curr. Drug Metab. 2003, 4:461-85.

[0210] Scheme 2 below provides a method of synthesizing an acyloxymethyl version of a prodrug by adapting a method from the reference Sobolev et al., 2002, J. Org. Chem. 67:401-410.

##STR00050##

[0211] wherein R.sup.51 is C.sub.1-C.sub.6 alkyl.

[0212] Scheme 3 below provides a method for synthesizing a phosphonooxymethyl version of a prodrug by adapting a method from Mantyla et al., 2004, J. Med. Chem. 47:188-195.

##STR00051##

[0213] Scheme 4 below provides a method of synthesizing an alkyloxymethyl version of a prodrug

##STR00052##

[0214] wherein R.sup.52 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.9 heterocyclyl, C.sub.6-C.sub.10 aryl, or C.sub.3-C.sub.9 heteroaryl.

[0215] From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

[0216] Throughout the description of this invention, reference is made to various patent applications and publications, each of which are herein incorporated by reference in their entirety.

Claims

1. A compound of formula (I): ##STR00053## or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof, wherein A is selected from the group consisting of: ##STR00054## wherein R.sup.1 is C.sub.1-C.sub.6 alkyl optionally substituted with 3-6 fluoro atoms; R.sup.2 is hydrogen or C.sub.1-C.sub.6 alkyl; R.sup.3 is C.sub.1-C.sub.6 alkyl; each R.sup.4 independently is hydrogen or C.sub.1-C.sub.6 alkyl; ring B is ##STR00055## or ring B together with A is: ##STR00056## X is oxygen, S, SO, or SO.sub.2; ring C is selected from the group consisting of: ##STR00057## wherein R.sup.5 is selected from the group consisting of hydrogen; C.sub.1-C.sub.6 alkoxy, optionally substituted with a C.sub.1-C.sub.6 alkoxy group or with up to 3 fluoro atoms; C.sub.1-C.sub.6 alkyl; and halo; R.sup.6 is hydrogen or halo; R is hydrogen, a phosphate, a diphosphate, a phosphonate or a phosphoramidate containing moiety, or another promoiety; provided that the compound of formula (I) comprises at least 1 OR group where R is not hydrogen.

2. The compound of claim 1, of formula (II): ##STR00058## wherein R and R.sup.1 are defined as in claim 1.

3. The compound of claim 1, wherein R is --C(O)R.sup.31, C(O)OR.sup.31, or CONR.sup.13R.sup.14 wherein each R.sup.31 is independently a C.sub.1-C.sub.6 alkyl; C.sub.3-C.sub.8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; and R.sup.13 and R.sup.14 independently are C.sub.1-C.sub.6 alkyl; C.sub.3-C.sub.8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; or R.sup.13 and R.sup.14 together with the nitrogen atom they are bonded to for a 4-9 member heterocycle substituted with at least 1 amino, C.sub.1-C.sub.6 alkyl amino, or di C.sub.1-C.sub.6 alkylamino group.

4. The compound of claim 1, wherein R.sup.1 is isopropyl.

5. A compound of formula (II): ##STR00059## wherein R is phosphate, C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35, or C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35; and wherein m, R.sup.1, R.sup.34 and R.sup.35 are defined as tabulated below: TABLE-US-00003 R R.sup.1 m R.sup.34 R.sup.35 NR.sup.34R.sup.35 C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 2 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 3 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 4 Me Me propyl C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 2 ##STR00060## C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 3 ##STR00061## C(O)(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 4 ##STR00062## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 2 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 3 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- 4 Me Me propyl C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 2 ##STR00063## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 3 ##STR00064## C(O)O(CH.sub.2).sub.mNR.sup.34R.sup.35 iso- propyl 4 ##STR00065## P(O)(OH).sub.2 iso- propyl

an N oxide thereof, or a pharmaceutically acceptable salt of each thereof.

6. A composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.

7. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

8. A method for treating oxygen deficiency associated with sickle cell anemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.